Postpartum Depression - Pipeline Insight, 2024

Postpartum Depression - Pipeline Insight, 2024

DelveInsight’s, “Postpartum Depression – Pipeline Insight, 2024,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Postpartum Depression Understanding

Postpartum Depression: Overview

The birth of a baby can trigger a jumble of powerful emotions, from excitement and joy to fear and anxiety. Most new moms experience postpartum ""baby blues"" after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues typically begin within the first two to three days after delivery, and may last for up to two weeks. But some new moms experience a more severe, long-lasting form of depression known as postpartum depression. Rarely, an extreme mood disorder called postpartum psychosis also may develop after childbirth. Postpartum depression isn't a character flaw or a weakness. Sometimes it's simply a complication of giving birth.

Symptoms

Signs and symptoms of depression after childbirth vary, and they can range from mild to severe.

• Baby blues symptoms

1. Mood swings

2. Anxiety

3. Sadness

4. Irritability

5. Feeling overwhelmed

6. Crying

7. Reduced concentration

8. Appetite problems

9. Trouble sleeping

• Postpartum depression signs and symptoms may include:

1. Depressed mood or severe mood swings

2. Excessive crying

3. Difficulty bonding with your baby

4. Withdrawing from family and friends

5. Loss of appetite or eating much more than usual

6. Inability to sleep (insomnia) or sleeping too much

7. Overwhelming fatigue or loss of energy

8. Reduced interest and pleasure in activities you used to enjoy

9. Intense irritability and anger

10. Fear that you're not a good mother

11. Hopelessness

12. Feelings of worthlessness, shame, guilt or inadequacy

13. Diminished ability to think clearly, concentrate or make decisions

14. Restlessness

15. Severe anxiety and panic attacks

16. Thoughts of harming yourself or your baby

17. Recurrent thoughts of death or suicide

Diagnosis

As part of evaluation, doctor may:

• Do a depression screening that may include having fill out a questionnaire
• Order blood tests to determine whether an underactive thyroid is contributing to signs and symptoms
• Order other tests, if warranted, to rule out other causes for the symptoms

Treatment

There are two main treatments for postpartum depression: medication and therapy. Either one can be used alone, but they may be more effective when used together. It’s also important to make some healthy choices in daily routine.

• Medication: Antidepressants have a direct effect on the brain. They alter the chemicals that regulate mood. They won’t work right away, though. It can take several weeks of taking the medication before the patients notice a difference in mood.
• Therapy: A psychiatrist, psychologist, or other mental health professional can provide counseling. Therapy can help make sense of destructive thoughts and offer strategies for working through them.

Postpartum Depression Emerging Drugs Chapters

This segment of the Postpartum Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postpartum Depression Emerging Drugs

• Zuranolone: Sage Therapeutics

Sage Therapeutics is conducting a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of SAGE-217 in the treatment of adults with severe postpartum depression. The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.

Further product details are provided in the report……..

Postpartum Depression: Therapeutic Assessment

This segment of the report provides insights about the different Postpartum Depression drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Postpartum Depression

There are approx. 2+ key companies which are developing the therapies for Postpartum Depression. The companies which have their Postpartum Depression drug candidates in the mid to advanced stage, i.e. phase III include, Sage Therapeutics and others.

Phases

DelveInsight’s report covers around 2+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postpartum Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postpartum Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postpartum Depression drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Postpartum Depression R&D. The therapies under development are focused on novel approaches to treat/improve Postpartum Depression.

Postpartum Depression Report Insights

• Postpartum Depression Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Postpartum Depression Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Postpartum Depression drugs?
• How many Postpartum Depression drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postpartum Depression?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postpartum Depression therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postpartum Depression and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sage Therapeutics
• Epharmix, Inc.

Key Products

• SAGE-217
• Epharmix